1
|
Horn D, Gross M, Dyckhoff G, Fuchs J, Grabe N, Weichert W, Herpel E, Herold‐Mende C, Lichter P, Hoffmann J, Hess J, Freier K. Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma. Head Neck 2018; 40:2685-2694. [DOI: 10.1002/hed.25515] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 08/21/2018] [Accepted: 10/06/2018] [Indexed: 01/01/2023] Open
Affiliation(s)
- Dominik Horn
- Department of Oral and Cranio‐Maxillofacial SurgeryUniversity Hospital Heidelberg Heidelberg Germany
| | - Madeleine Gross
- Department of Oral and Cranio‐Maxillofacial SurgeryUniversity Hospital Heidelberg Heidelberg Germany
- Division of Molecular GeneticsGerman Cancer Research Center (DKFZ) Heidelberg Germany
| | - Gerhard Dyckhoff
- Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Hospital Heidelberg Heidelberg Germany
- Molecular Cell Biology Group, Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Hospital Heidelberg Heidelberg Germany
| | - Jennifer Fuchs
- Department of Oral and Cranio‐Maxillofacial SurgeryUniversity Hospital Heidelberg Heidelberg Germany
| | - Niels Grabe
- Hamamatsu Tissue Imaging and Analysis Center (TIGA)BIOQUANT, University of Heidelberg Heidelberg Germany
| | - Wilko Weichert
- Institute of PathologyUniversity Hospital Heidelberg Heidelberg Germany
| | - Esther Herpel
- Institute of PathologyUniversity Hospital Heidelberg Heidelberg Germany
- Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg Germany
| | - Christel Herold‐Mende
- Molecular Cell Biology Group, Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Hospital Heidelberg Heidelberg Germany
| | - Peter Lichter
- Division of Molecular GeneticsGerman Cancer Research Center (DKFZ) Heidelberg Germany
| | - Jürgen Hoffmann
- Department of Oral and Cranio‐Maxillofacial SurgeryUniversity Hospital Heidelberg Heidelberg Germany
| | - Jochen Hess
- Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Hospital Heidelberg Heidelberg Germany
- Research Group Molecular Mechanisms of Head and Neck TumorsGerman Cancer Research Center (DKFZ) Heidelberg Germany
| | - Kolja Freier
- Department of Oral and Cranio‐Maxillofacial SurgeryUniversity Hospital Heidelberg Heidelberg Germany
| |
Collapse
|
2
|
Pizzi M, Trentin L, Visentin A, Saraggi D, Martini V, Guzzardo V, Righi S, Frezzato F, Piazza F, Sabattini E, Semenzato G, Rugge M. Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Hum Pathol 2018; 85:251-259. [PMID: 30458196 DOI: 10.1016/j.humpath.2018.10.038] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2018] [Revised: 10/24/2018] [Accepted: 10/31/2018] [Indexed: 11/29/2022]
Abstract
Cortactin is a cytoskeletal-remodeling adaptor protein, playing an oncogenic role in solid tumors. Little is known on cortactin expression in non-Hodgkin B-cell lymphomas (B-NHLs). The present study aimed to characterize cortactin expression in B-NHLs and to assess its role in the differential diagnosis of such entities. Cortactin protein expression was first assessed by immunohistochemistry in a series of 131 B-NHLs, including B-cell chronic lymphocytic leukemia (CLL; n = 17), mantle cell lymphoma (MCL; n = 16), follicular lymphoma (FL; n = 25), marginal zone lymphoma (MZL; n = 30), hairy cell leukemia (HCL; n = 10), splenic diffuse red pulp small B-cell lymphomas (SDRPBL; n = 3), and diffuse large B-cell lymphoma (DLBCL; n = 30) cases. Cortactin was expressed in 14 of 17 CLLs, 10 of 10 HCLs, and 22 of 30 DLBCLs. MCLs, SDRPBLs, most FLs, and MZLs were cortactin negative. The immunohistochemical results were in keeping with in silico gene expression data. In CLL, cortactin positivity did correlate with LEF1 and CD200 expression, and the combined positivity for ≥2 markers strongly predicted CLL diagnosis. Such preliminary data suggested a role for cortactin in the differential diagnosis between CLL and MCL. This hypothesis was confirmed in a large validation set of 112 CLLs (n = 55) and MCLs (n = 57), which also disclosed rare cortactin-expressing MCLs. The immunohistochemical and gene expression results were sustained by flow cytometry and Western blot analysis on CLL and MCL cell lines. In conclusion, cortactin is mainly expressed in subsets of CLL and DLBCL and in HCL. Cortactin may represent a novel marker for the differential diagnosis between CLL and MCL.
Collapse
Affiliation(s)
- Marco Pizzi
- General Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35121 Italy.
| | - Livio Trentin
- Hematology and Clinical Immunology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35128 Italy
| | - Andrea Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35128 Italy
| | - Deborah Saraggi
- General Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35121 Italy
| | - Veronica Martini
- Hematology and Clinical Immunology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35128 Italy
| | - Vincenza Guzzardo
- General Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35121 Italy
| | - Simona Righi
- Hematopathology Unit, Department of Hematology and Oncology, Sant'Orsola University Hospital, Bologna, 40138 Italy; Department of Experimental Diagnostic and Specialty Medicine, Sant'Orsola University Hospital, Bologna, 40138 Italy
| | - Federica Frezzato
- Hematology and Clinical Immunology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35128 Italy
| | - Francesco Piazza
- Hematology and Clinical Immunology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35128 Italy
| | - Elena Sabattini
- Hematopathology Unit, Department of Hematology and Oncology, Sant'Orsola University Hospital, Bologna, 40138 Italy; Department of Experimental Diagnostic and Specialty Medicine, Sant'Orsola University Hospital, Bologna, 40138 Italy
| | - Gianpietro Semenzato
- Hematology and Clinical Immunology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35128 Italy
| | - Massimo Rugge
- General Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35121 Italy
| |
Collapse
|
3
|
High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol 2018; 35:71. [PMID: 29651632 DOI: 10.1007/s12032-018-1132-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 04/08/2018] [Indexed: 01/23/2023]
Abstract
Metastatic spread of the cancer is usually the consequence of the activation of signaling pathways that generate cell motility and tissue invasion. Metastasis involves the reorganization of cytoskeleton and cell shape for the swift movement of the cells through extracellular matrix. Previously, we have described the invasive and metastatic role played by one of the members (Toca-1) of CIP4 subfamily of F-BAR proteins. In the present study, we address the role of another member (FBP17) of same family in the invasion breast cancer cells. Here, we report that the formin-binding protein 17 (FBP17) is highly expressed at both mRNA and protein levels in breast cancer cells. The study showed the association of FBP17 with cytoskeletal actin regulatory proteins like dynamin and cortactin. To determine its role in extracellular matrix (ECM) degradation, we achieved stable knockdown of FBP17 in MDA-MB-231 cells. FBP17 knockdown cells showed a defect and were found to be compromised in the degradation of ECM indicating the role of FBP17 in the invasion of breast cancer cells. Our results suggest that FBP17 is highly expressed in breast cancer cells and facilitates the invasion of breast cancer cells.
Collapse
|
4
|
Siar CH, Rahman ZABA, Tsujigiwa H, Mohamed Om Alblazi K, Nagatsuka H, Ng KH. Invadopodia proteins, cortactin, N-WASP and WIP differentially promote local invasiveness in ameloblastoma. J Oral Pathol Med 2016; 45:591-8. [PMID: 26752341 DOI: 10.1111/jop.12417] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/10/2015] [Indexed: 01/17/2023]
Abstract
BACKGROUND Cell migration and invasion through interstitial tissues are dependent upon several specialized characteristics of the migratory cell notably generation of proteolytic membranous protrusions or invadopodia. Ameloblastoma is a benign odontogenic epithelial neoplasm with a locally infiltrative behaviour. Cortactin and MMT1-MMP are two invadopodia proteins implicated in its local invasiveness. Other invadopodia regulators, namely N-WASP, WIP and Src kinase remain unclarified. This study addresses their roles in ameloblastoma. MATERIALS AND METHOD Eighty-seven paraffin-embedded ameloblastoma cases (20 unicystic, 47 solid/multicystic, 3 desmoplastic and 17 recurrent) were subjected to immunohistochemistry for expression of cortactin, N-WASP, WIP, Src kinase and F-actin, and findings correlated with clinicopathological parameters. RESULTS Invadopodia proteins (except Src kinase) and F-actin were widely detected in ameloblastoma (cortactin: n = 73/87, 83.9%; N-WASP: n = 59/87; 67.8%; WIP: n = 77/87; 88.5%; and F-actin: n = 87/87, 100%). Protein localization was mainly cytoplasmic and/or membranous, and occasionally nuclear for F-actin. Cortactin, which functions as an actin-scaffolding protein, demonstrated significantly higher expression levels within ameloblastoma tumoral epithelium than in stroma (P < 0.05). N-WASP, which coordinates actin polymerization and invadopodia-mediated extracellular matrix degradation, was overexpressed in the solid/multicystic subtype (P < 0.05). WIP, an upstream regulator of N-WASP, and F-actin were significantly upregulated along the tumour invasive front compared to tumour centres (P < 0.05). Except for males with cortactin overexpression, other clinical parameters (age, ethnicity and anatomical site) showed no significant correlations. CONCLUSIONS Present results suggest that local invasiveness of ameloblastoma is dependent upon the migratory potential of its tumour cells as defined by their distribution of cortactin, N-WASP and WIP in correlation with F-actin cytoskeletal dynamics.
Collapse
Affiliation(s)
- Chong Huat Siar
- Department of Oro-Maxillofacial Surgical and Medical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Zainal Ariff Bin Abdul Rahman
- Department of Oro-Maxillofacial Surgical and Medical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Hidetsugu Tsujigiwa
- Laboratory of Histopathology, Department of Life Science, Faculty of Science, Okayama University of Science, Okayama, Japan
| | - Kamila Mohamed Om Alblazi
- Department of Oro-Maxillofacial Surgical and Medical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Hitoshi Nagatsuka
- Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
| | - Kok Han Ng
- Unit of Stomatology, Cancer Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia
| |
Collapse
|